Stockscreener 앱 받기
18.32
6.20%
-1.21
전일 마감가:
$19.53
열려 있는:
$19.09
하루 거래량:
261.02K
Relative Volume:
0.98
시가총액:
$2.34B
수익:
$7.50M
순이익/손실:
$-81.89M
주가수익비율:
0.3455
EPS:
53.0176
순현금흐름:
$-63.58M
1주 성능:
-0.49%
1개월 성능:
+17.74%
6개월 성능:
+76.15%
1년 성능:
+96.36%
1일 변동 폭
$18.10
$19.17
1주일 범위
$17.08
$20.18
52주 변동 폭
$7.09
$22.00
Mesoblast Ltd Adr Stock (MESO) Company Profile
MESO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MESO
Mesoblast Ltd Adr
|
18.32 | 2.50B | 7.50M | -81.89M | -63.58M | 53.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Mesoblast Ltd Adr Stock (MESO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-12-23 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-09-24 | 업그레이드 | Maxim Group | Hold → Buy |
| 2024-08-29 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-07-23 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-08-31 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-07 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2023-08-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-08-04 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-03-09 | 개시 | William Blair | Outperform |
| 2022-12-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-09-06 | 개시 | Piper Sandler | Overweight |
| 2021-04-07 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-12-22 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-12-04 | 다운그레이드 | Chardan Capital Markets | Neutral → Sell |
| 2020-10-22 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-08-14 | 재확인 | Maxim Group | Buy |
| 2020-05-28 | 재확인 | H.C. Wainwright | Buy |
| 2019-01-31 | 재개 | H.C. Wainwright | Buy |
| 2018-03-22 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2018-02-28 | 재확인 | Cantor Fitzgerald | Buy |
| 2017-08-31 | 개시 | Oppenheimer | Outperform |
| 2017-06-08 | 개시 | Cantor Fitzgerald | Buy |
모두보기
Mesoblast Ltd Adr 주식(MESO)의 최신 뉴스
Ryoncil® Revenues Increase 66% in Second Quarter Post Launch - GlobeNewswire Inc.
Quantum Computing, Mesoblast And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Mesoblast Limited $MESO Shares Acquired by Cubist Systematic Strategies LLC - Defense World
Mesoblast Secures Option for US$50 Million Convertible Note Issuance - Sharecafe
Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes - ADVFN Brasil
Mesoblast secures up to US$50m in fresh funding through convertible note agreements - Biotech Dispatch
Canaccord Genuity initiates Mesoblast stock with Buy rating on cell therapy potential - Investing.com
Company’s Banking Stock: Dissecting a -4.28% Quarterly Revenue Decline Amid Growth - investchronicle.com
Novagold Resources Inc (NG) Stock: A Year of Decreases and Increases - investchronicle.com
TV’s 2025 Market Dance: Down -20.11% – Time to Invest? - investchronicle.com
Mesoblast Ltd ADR Inc. (MESO) Price Performance: A Comparative Analysis with Competitors - investchronicle.com
Cango Inc ADR (CANG) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - investchronicle.com
Innodata Inc (INOD) Stock: A Year of Market Movement, Down and Up - investchronicle.com
BILL Holdings Inc Inc. (BILL) Price Performance: A Fundamental Analysis Perspective - investchronicle.com
Burford Capital Limited: Navigating Market Fluctuations with a 3.10B Market Cap - investchronicle.com
Chagee Holdings Ltd. ADR (CHA) Stock: A Year of Highs and Lows - investchronicle.com
Nano X Imaging Ltd (NNOX) Stock: The Story of a 52-Week Stock Range - investchronicle.com
WGRX Stock Update: Wellgistics Health Inc’s Banking’s Market Struggles and Potential Opportunities - investchronicle.com
ZTO’s Stock Market Adventure: -5.37% YTD Growth Amidst Volatility - investchronicle.com
MGRX’s Market Whiplash: -74.88% YTD Decline, -16.49% Plunge in 30 Days - investchronicle.com
Mesoblast stock soars after reporting first Ryoncil sales - Investing.com India
Sonim Technologies Inc (SONM) Stock: Uncovering 52-Week Market Trends - investchronicle.com
An In-Depth Look at Trident Digital Tech Holdings Ltd. ADR Inc. (TDTH) Price Performance During Market Crashes - investchronicle.com
BTCM: Riding the Market Waves of Growth and Decline in 2025 - investchronicle.com
Perspective Therapeutics Inc (CATX Stock: A Sea of Opportunity - investchronicle.com
DallasNews Corporation (DALN) Stock: Uncovering 52-Week Market Trends - investchronicle.com
DraftKings Inc (DKNG) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com
TSM’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor - Sahm
Krispy Kreme Inc (DNUT) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Why Cheetah Mobile Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket - Benzinga
All Markets & Instruments Available to Trade - Capital.com
ASX Lunch Wrap: ASX and gold reset record highs; but Origin cuts its LNG forecast - Stockhead
Why are Mesoblast shares in a trading halt? - The Motley Fool Australia
Mesoblast Limited Initiates Trading Halt Pending Financing Announcement - TipRanks
ASX December health sector winners… and a 91pc drop for a trial-flopped stock - Stockhead
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
Mesoblast Stock Soars to 52-Week High, Hits $19.15 - Investing.com
Mesoblast stock soars to 52-week high, hits $12.21 - Investing.com
Mesoblast Stock Soars to 52-Week High, Hits $12.19 - Investing.com
Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential (NASDAQ:MESO) - Seeking Alpha
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners - Stockhead
Mesoblast Limited: Back From The Dead (NASDAQ:MESO) - Seeking Alpha
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - TradingView
11 Best ASX Stocks To Buy Now - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
10 Best Australian Stocks To Buy - Yahoo Finance
Philip R. Krause, M.D., Former FDA Deputy Chief For Vaccines, Joins Mesoblast Board - Barchart.com
Maxim Group Stick to Their Buy Rating for Mesoblast Ltd - Investing.com
Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy - Novartis
ASX dives as Trump tests COVID positive - The Australian
Mesoblast Ltd Adr (MESO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.74%
자본화:
|
볼륨(24시간):